Vergoeding 2020-2024 voor ATC-subgroep L01EX : Overige proteinekinaseremmers
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023* | 2024* | |
|---|---|---|---|---|---|
| L01EX01 Sunitinib | 6.895.475 | 6.548.581 | 3.606.259 | 1.426.072 | 692.629 |
| L01EX02 Sorafenib | 1.798.610 | 1.301.651 | 1.005.253 | 691.721 | 424.493 |
| L01EX03 Pazopanib | 7.260.533 | 5.613.984 | 4.829.414 | 3.761.762 | 3.121.482 |
| L01EX04 Vandetanib | 889.460 | 1.041.173 | 893.049 | 767.805 | 724.460 |
| L01EX05 Regorafenib | 751.538 | 693.085 | 710.842 | 562.090 | 515.330 |
| L01EX07 Cabozantinib | 11.706.782 | 11.620.121 | 8.121.916 | 8.624.154 | 6.939.417 |
| L01EX08 Lenvatinib | 3.059.453 | 3.462.607 | 3.175.048 | 2.867.528 | 2.522.173 |
| L01EX09 Nintedanib | 176.971 | 163.112 | 173.063 | 82.334 | . |
| L01EX10 Midostaurine | 4.266.839 | 3.661.092 | 3.532.130 | 4.692.564 | 4.590.619 |
| L01EX12 Larotrectinib | . | 10.205 | 269.454 | 404.142 | 499.487 |
| L01EX13 Gilteritinib | . | 804.323 | 1.269.234 | 1.783.253 | 1.528.920 |
| L01EX14 Entrectinib | . | . | 58.315 | 113.909 | 57.265 |
| L01EX18 Avapritinib | . | 336.389 | 1.997.673 | 764.189 | 910.051 |
| L01EX21 Tepotinib | . | . | 9.267 | 852.497 | 1.349.696 |
| L01EX22 Selpercatinib | . | 75.243 | 3.037.008 | 4.511.379 | 5.348.386 |
| Totaal | 36.805.661 | 35.331.567 | 32.687.924 | 31.905.397 | 29.224.407 |